Expert Consensus on Clinical Use and Management of High Concentration of Potassium Chloride Injection in Yunnan Province （2020）
- VernacularTitle:云南省高浓度氯化钾注射液临床使用与管理专家共识（2020）
- Author:
Center YUNNAN
1
;
Center YUNNAN
2
;
Association Nursing YUNNAN
3
;
Association INTENSIVE
4
;
Association PHARMACY
5
;
Society CLINICAL
5
;
Association CARDIAC
5
;
Province WRITING
5
Author Information
1. High concentrati on potassium chloride injection
2. Yunnan
3. Clinical Use
4. Management
5. Expert Consensus
- Publication Type:Journal Article
- Keywords:
High concentrati on potassium chloride injection;
Yunnan;
Clinical Use;
Management;
Expert Consensus
- From:
China Pharmacy
2021;32(2):129-132
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To provide sugge stions for improving the variety of pediatric drugs and ensuring the safety of pediatric drug use in China. METHODS ：The historical evolution of laws and regulations on the marketing approval of pediatric drugs in the United States and the implementation results of relevant policies were summarized. Combined with the current situation of the development of pediatric drugs in China ，some suggestions were put forward to ensure the accessibility and safety of pediatric drug use in China. RESULTS & CONCLUSIONS ：Since 1994，the United States had issued a series of laws and regulations to encourage the development of pediatric drugs. At present ，the marketing approval of pediatric drugs were mainly based on the two laws of Best Pediatric Drug Act（BPCA）and Pediatric Research Equality Act （PREA）. From 1998 to 2019，the amount of supplements of pediatric drug information in drug instructions of the United States showed a fluctuating growth. As of April 2020，854 kinds of drugs had been modified in pediatric instructions ，792 of which had been carried out post marketing pediatric clinical research ，and the problem of incomplete pediatric instructions had also been greatly improved. At present ，China’s policies on pediatric drugs mainly included encouraging R&D innovation ，giving priority to review and approval ，and strengthening R&D technical guidance. Although certain achievements had been made ，there were still some problems ，such as imperfect policies and regulations ，and great difficulties carrying out pediatric drug clinical trials. It is suggested that our country should draw lessons from the American regulations on pediatric drugs ，pediatric research and the catalogue of pediatric drugs ，and establish a system and catalogue of ped iatric drug use suitable for China ’s national conditions ，so as to improve the effectiveness ，safety and accessibilityof pediatric drugs.
